

European Journal of Chemistry

Journal homepage: www.eurjchem.com

Substituted Quinolinones. Part 16. Preparation and reactions of 3-(4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-3-oxopropanoic acid

Mohamed Abass^{a,*}, Elhossain Ali Mohamed^a, Mostafa Mohamed Ismail^a and Aisha Saleh Mayas^b

^a Department of Chemistry, Faculty of Education, Ain Shams University, Roxy, Cairo, 11757, Egypt ^b Department of Chemistry, Faculty of Education, Sana'a University, Sana'a, Yemen

*Corresponding author at: Department of Chemistry, Faculty of Education, Ain Shams University, Roxy, Cairo, 11757, Egypt. Tel.: +2.0193694622.; fax: +2.0222581243. E-mail address: m.abass@chemist.com (M. Abass).

ARTICLE INFORMATION

Received: 27 November 2010 Received in revised form: 05 January 2011 Accepted: 06 January 2011 Online: 30 September 2011

KEYWORDS

Quinolin-2(1*H*)-one β-Keto-carboxylic acid Pyrano[3,2-c]quinoline Knoevenagel condensation Heterocyclization reactions Organic synthesis

1. Introduction

ABSTRACT

Preparation of quinolinyl-3-oxopropanoic acid was accomplished by hydrolysis of pyranoquinolinedione, in aqueous alkaline medium. The chemical behavior of this β -keto acid towards nitrosation, coupling with a diazonium salt, esterification, condensation with 2,2-diethoxyethanamine, hydrazinolysis, Knoevenagel condensation with isatine, salicylaldehyde, 3-formylquinolones, and 3-formylchromone, was investigated. Also many of the products of these reactions were obtained using either pyranoquinolinedione 1 or β -keto acid 2, under the same conditions.

In the recent years, an increasing interest in the synthesis of functionalized 4-hydroxyquinolin-2(1*H*)-ones, with important biological properties has been observed. A broad number of important pharmacological activities have been associated with 3-substituted 4-hydroxyquinolin-2(1H)-ones [1-5]. Many derivatives of this biologically active heterocyclic category are naturally occurring compounds, which were found as useful intermediates for many medicinal products [6-8]. It had been reported that N-methyl derivatives of 4hydroxyquinolin-2(1H)-one are associated with significant biological activity [9-11], and many derivatives of 6methylpyrano[3,2-c]quinolinone are known as pharmaceutical active ingredients, e.g. the well-known alkaloids: veprisines and flindersines [12,13]. Pyrano[3,2-c]quinolinones were found to be active against certain immuno-reaction diseases, in particular against immediate hypersensitivity reactions (anaphylaxis). Furthermore, they were distinguished by a strong systemic antiallergic action and therefore, they are suitable for the treatment and the prophylaxis of allergy diseases [14]. In general, most of these medicines include 4oxyquinolin-2-one as the stem heterocyclic system. Thus, the majority of the viable syntheses of this category of compounds employed the cyclization of the corresponding 4hydroxyquinolin-2(1H)-ones. In turn these pyranoquinolinones were used on wide range to obtain 4-hydroxyquinolin-2(1H)one and 3-acetyl-4-hydroxyquinolin-2(1H)-one derivatives [15]. So that 4-hydroxypyrano[3,2-*c*]quinoline-2,5(6*H*)-diones are very important synthons to obtain several 3-substituted 4hydroxyquinolin-2(1H)-ones especially 3-acyl derivatives [16,17]. Recently, Razzaq et al. [18] had described a rapid preparation of pyranoquinolinone 1 using microwave assisted conditions. Earlier, Bowman et al. [19] had reported one pot synthesis of 4-hydroxypyrano[3,2-c]quinoline-2,5(6H)-diones by condensation of the appropriate aniline with excess diethyl malonate, a technique which is still the most successful procedure to obtain such heterocyclic system and we apply to this methodology in order to prepare our starting material; pyranoquinolinone 1. In connection to our program work which deals with substituted quinolinones, our attention was directed to obtain new multi-functionalized quinolinone derivatives of expected biological activity especially as antimalarial and antiparasitic [1,2]. In the present work, we describe the synthetic utility of pyranoquinolinone 1 and its alkaline hydrolysis product; 3-(4-hydroxy-1-methyl-2-oxo-1,2dihydroquinolin-3-yl)-3-oxopropanoic acid, 2, to obtain new heterocyclic derivatives incorporating quinoline-2-one moiety of expected antiparasitic activity.

2. Experimental

2.1. General

Melting points are uncorrected and were determined on a digital Stuart-SMP3 apparatus. IR spectra were taken on a Perkin-Elmer FT-IR 1650 in KBr disks. ¹H NMR spectra were recorded on Varian Gemini-200 NMR-spectrometer (200 MHz), using DMSO- d_6 or CDCl₃ as solvents and TMS as internal reference. Mass spectra were determined on a Shimadzu GC-MS-QP 1000 EX mass spectrometer at 70 eV.

European Journal of Chemistry ISSN 2153-2249 (Print) / ISSN 2153-2257 (Online) © 2011 EURJCHEM DOI:10.5155/eurjchem.2.3.378-387.351



Scheme 1

Elemental microanalyses were performed on a Perkin Elmer CHN-2400 Analyzer. All reactions were monitored by thin-layer chromatography (TLC) on 0.2-mm silica gel F-254 (Merck) plates, using UV light (254 and 366 nm) for detection. Authentic samples of compounds **1** [20], **3b** [21], **9** [16], **14a** [22], **14b** [23], **18** [24] and **21** [25] were prepared according to the literature methods.

2.2. 4-Hydroxy-6-methylpyrano[3,2-c]quinoline-2,5(6H)dione (1)

2.2.1. Procedure A

The β -keto acid **2** (1.3 g, 5 mmol) was portion-wise added to concentrated sulfuric acid (10 mL) with continuous stirring where the internal temperature was kept 60-65 °C by means of thermostated water-bath. After completion of addition the mixture was stirred at the ambient temperature for 2 hr, and then poured onto crushed ice to give a brown precipitate. The precipitate so formed was filtered, washed with cold ethanol and crystallized to give the pyranoquinolinone, **1** [20] (Scheme **1**) (Table 1 and 2).

2.2.2. Procedure B

A solution of the ester derivative **3a** (0.29 g, 1 mmol), in DMF (10 mL), was heated under reflux for 4 h. Then, the reaction mixture was left to cool, at room temperature, and the crystalline precipitate so formed was filtered and recrystallized to give the pyranoquinolinone, **1**.

2.3. 3-(4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-3-oxopropanoic acid (2)

The compound **1** (2.43 g, 10 mmol) was dissolve in sodium hydroxide solution (20 mL, 2M) and warmed at \sim 50 °C for 30 min, and then the solution so obtained was filtered off. The clear solution was precipitated by dilute hydrochloric acid. The precipitate was filtered, washed with water, dried and crystallized (Scheme 1) (Table 1 and 2).

2.4. Methyl 3-(4-Hydroxy-1-methyl-2-oxo-1,2-dihydro quinolin-3-yl)-3-oxopropanoate (3a) and Ethyl 3-(4hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-3-oxo propanoate (3b)

To a suspension of the compound **2** (2.61 g, 10 mmol), in the proper alcohol *viz*; absolute methanol and/or ethanol (20 mL), concentration sulfuric acid (5 mL) was added and stirred up at room temperature overnight. The precipitate so formed was filtered, washed with water, dried, and crystallized to give the esters **3a** and **3b** [21] (Scheme 1) (Table 1 and 2).

2.5. 3-(4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-2-oximo-3-oxopropanoic Acid (4)

To a previously cooled solution (0-5 °C) of the β -keto acid **2** (1.3 g, 5 mmol), in aqueous sodium carbonate (50 mL, 1 M), was drop-wise added nitrous acid (freshly prepared from solution of sodium nitrate (0.35 g, 5 mmol) in ice-cold water (10 mL), and hydrochloric acid (60 mL, 1 M) with continuous stirring for about 30 min.



After completion of addition at, the mixture was stirred at the ambient temperature. The bright orange precipitate that formed was filtered, washed several times with cold water, dried and crystallized to give the oxime **4** (Scheme 2) (Table 1 and 2).

2.6. 6-Methyl-3-oximopyrano[3,2-c]quinoline-2,4,5(3H,6H)trione (5)

2.6.1. Procedure A

The compound **4** (0.58 g, 2 mmol) was portion-wise added to concentrated sulfuric acid (5 mL) and stirred at room temperature for 2 hr. The dark brick red solution so formed

was poured onto crushed ice. The separated deep orange deposits were filtered, washed with cold water several time, dried and crystallized to give the oximopyranoquinoline **5** (Scheme 2) (Table 1 and 2).

2.6.2. Procedure B

To a previously cooled solution (0-5 °C) the compound **1** (1.22 g, 5 mmol), in aqueous sodium carbonate (50 mL, 1M), was drop-wise added nitrous acid (freshly prepared from solution of sodium nitrate (0.35 g, 5 mmol) in ice-cold water (10 mL), and hydrochloric acid (60 mL, 1 M) with continuous stirring for about 30 min. After completion of addition at, the mixture was stirred at the ambient temperature.

Compound	Yield,	M.p., °C	Formula	Analysis Calculated/Found		
No.	%	Crystallization solvent	M.wt., g	С%	H%	N%
1	90ª	255-257°	C ₁₃ H ₉ NO ₄	64.20	3.73	05.76
	76 ^b	Dioxane	243.22	64.00	3.70	05.60
2	94	225-227	C13H11NO5	59.77	4.24	05.36
		DMF	261.24	59.80	4.20	05.40
3a	85	120-122	C14H13NO5	61.09	4.76	05.09
		Dioxane	275.26	61.2 0	4.80	04.80
3b	83	130-132 ^d	C15H15NO5	62.28	5.23	04.84
		Dioxane	289.29	62.00	5.30	04.80
4	70	244-245	$C_{13}H_{10}N_2O_6$	53.80	3.47	09.65
		CHCl ₃	290.23	53.80	3.50	09.70
5	60ª	190-191	C13H8N2O5	57.36	2.96	10.29
	76 ^b	DMSO	272.22	57.30	2.90	10.00
6	67	250-252	$C_{19}H_{14}N_4O_7$	55.61	3.44	13.65
		EtOH	410.35	55.50	3.30	13.40
7	81ª	275-276	C19H12N4O6	58.17	3.08	14.28
	80 ^b	DMF	392.33	58.10	3.10	14.40
8	67	200-201	$C_{16}H_{14}N_2O_4$	64.42	4.73	09.39
		DMF	298.30	64.40	4.60	09.20
9	56	284-285 ^e	C13H11N3O3	60.70	4.31	16.33
		DMSO	257.25	60.5 0	4.40	16.00
10	75	>300	$C_{21}H_{14}N_2O_6$	64.62	3.62	07.18
		AcOH	390.36	64.50	3.50	07.00
11	70 ^e	>300	C21H12N2O5	67.74	3.25	07.52
	88 ^f	DMF	372.34	67.70	3.20	07.50
12	90	290-292	C20H13NO5	69.16	3.77	04.03
		DMSO	347.33	69.30	3.60	03.80
13	79 ^f	>300	C ₂₀ H ₁₃ NO ₅	69.16	3.77	04.03
		DMF	347.33	69.10	3.70	04.00
17a	74 ^a	>300	$C_{24}H_{16}N_2O_6$	67.29	3.76	06.54
	65 ^b	AcOH	428.40	67.50	3.50	06.40
17b	79 ^a	>300	$C_{24}H_{16}N_2O_6$	67.29	3.76	06.54
	68 ^f	AcOH	428.40	67.40	3.60	06.40
20	65	>300	C23H13NO6	69.17	3.28	03.51
		DMF	399.36	69.10	3.00	03.40
21	13	224-226	C22H15NO5	70.77	4.05	03.75
		DMF	373.37	70.60	3.80	03.50

^a Yield according to Procedure A.

^b Yield according to Procedure B.

° Literature [22] M.p.: 257 °C.

^d Literature [21] M.p.: 132 °C.

^e Literature [3] M.p.: 287-288 °C.

The deep orange precipitate that formed was filtered, washed several times with cold water, dried and crystallized to give the oximopyranoquinoline **5** (Scheme 2) (Table 1 and 2).

2.7. 3-(4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-2-[(4-nitro-phenyl)hydrazono]-3-oxopropionic acid (6)

To a previously cooled solution (0-5 °C) of the β -keto acid **2** (1.3 g, 5 mmol,) in sodium carbonate (50 mL, 1 M), was added a solution of *p*-nitrophenyldiazonium chloride, freshly prepared from *p*-nitroaniline (0.7 g, 5 mmol) and hydrochloric acid (60 mL, 1 M), with continuous stirring for about 30 min. After completion of addition, the mixture was stirred at the ambient temperature for 1 hr. The shining orange precipitate that formed was filtered, washed several times with cold water, dried and crystallized to give the hydrazone **6** (Scheme 2) (Table 1 and 2).

2.8. 6-Methyl-3-(4-nitrophenyl)hydrazonopyrano[3,2c]quinoline-2,4,5(3H,6H)-trione (7)

2.8.1. Procedure A

The compound **6** (0.82 g, 2 mmol) was portion-wise added to concentrated sulfuric acid (5 mL) and stirred at room temperature for 2 hr. The dark brick red solution so formed was poured onto crushed ice and the separated reddish-orange deposits were filtered, washed with cold water several time, dried and crystallized to give the hydrazonopyranoquinoline **7** (Scheme 2) (Table 1 and 2).

2.8.2. Procedure B

To a previously cooled solution (0-5 °C) of the compound **1** (1.22 g, 2 mmol,) in sodium carbonate (50 mL, 1 M), was added a solution of *p*-nitrophenyldiazonium chloride, freshly prepared from *p*-nitroaniline (0.7 g, 5 mmol) and hydrochloric acid (60 mL, 1 M), with continuous stirring for about 30 min. After completion of addition, the mixture was stirred at the ambient temperature for 1 hr. The reddish-orange precipitate that formed was filtered, washed twice with cold water, dried and crystallized give the hydrazonopyranoquinoline **7** (Scheme 2) (Table 1 and 2).

2.9. 2-(4-Methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-1H-pyrrole-3-carboxylic acid (8)

A mixture of the compound **2** (0.26 g, 1 mmol) and 2,2diethoxyethanamine (0.22 mL, 2 mmol), in DMF (10 mL), was heated under reflux for 6 hr. Then the solvent was evaporated in vacuum. The residual semi-solid material was triturated with cold ethanol (5 mL). The solid material so formed was filtered and crystallized give the pyrrolylquinoline **8** (Scheme 3) (Table 1 and 2).

2.10. 4-Hydroxy-1-methyl-3-(5-oxo-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one (9)

To a solution of the β -keto acid derivative 30~(0.52~g,~2~mmol), in DMF (10 mL), was added hydrazine hydrate (0.1 mL,



Scheme 3

2 mmol), and then the mixture was heated under reflux for 2 hr. The solid product, that formed, was filtered and crystallized to give the pyrazolylquinoline **9** [16] (Scheme 3) (Table 1 and 2).

2.11. 3-(4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-3-oxo-2-(2-oxoindolin-3-ylidene)propanoic acid (10)

A mixture of the compound **2** (0.26 g, 1 mmol), isatine (0.15 g, 1 mmol), and fused sodium acetate (0.5 g, 6 mmol) in acetic acid (20 mL), was heated under reflux for 4 hr. The brown crystalline material so formed was filtered and recrystallized to give the indoline derivative **10** (Scheme 4) (Table 1 and 2).

2.12. 6-Methyl-3-(2-oxoindolin-3-ylidene)-2H-pyrano[3,2-c] quinoline-2,4,5(3H,6H)-trione (11)

2.12.1. Procedure A

The compound **10** (0.29 g, 1 mmol) was portion-wise added to concentrated sulfuric acid (5 mL) and stirred at room temperature for 2 hr. The dark green solution so formed was poured onto crushed ice and the separated pale-yellow deposits were filtered, washed with cold water several time,

dried and crystallized to give the indoline **11** (Scheme 4) (Table 1 and 2).

2.12.2. Procedure B

A mixture of the compound **29** (0.25 g, 1 mmol), isatine (0.15 g, 1 mmol), and fused sodium acetate (0.5 g, 6 mmol) in acetic acid (20 mL), was heated under reflux for 4 hr. The paleyellow crystalline material so formed was filtered and recrystallized to give the indoline **11** (Scheme 4) (Table 1 and 2).

2.13. 4-Hydroxy-1-methyl-3-(2-oxo-2H-chromene-3-carbonyl)quinolin-2(1H)-one (12)

A mixture of the β -keto acid **2** (2.61 g, 10 mmol), salicylaldehyde (1 mL, 10 mmol), and piperidine (0.2 mL), in ethanol (50 mL), was heated under reflux for 4 hrs. The pastelyellow precipitate so obtained was filtered, washed thoroughly with cold ethanol and crystallized to give the coumarin **12** (Scheme 4) (Table 1 and 2).

Table 2. IR an	. IR and ¹ H NMR spectral data of the new compounds.				
No.		⁴ H NMR (DMSO- <i>u</i> ₆) , <i>o</i>	Mass, 11/2 (1; 70)		
2	3447-2951 (OH), 1734 (C=O _{carboxylic}), 1672 (C=O _{ketone}), 1615 (C=O _{quinolone})	(CDCl ₃): 3.79 (s, 3H, NCH ₃), 3.88 (s, 2H, CH ₂), 5.66 (s, 0.5H, 3-H), 7.26 (d, 1H, <i>J</i> = 8, 8-H), 7.50 (dd, 1H, <i>J</i> = 7.8, 2.0, 6-H), 7.80 (dd, 1H, <i>J</i> = 7.8, 2.0, 7-H), 8.32 (d, 1H, <i>J</i> = 8, 5-H), 13.60 (bs, 0.5H, OH), 15.60 (bs, 1H, OH _{carboxylic})	261 (4.1) (M ⁺), 243 (M ⁺ - H ₂ O) (22.8), 245 (3.6), 244 (8.4), 217 (23.3), 215 (100), 216 (17.6), 131 (32.4), 106 (11.3), 89 (37.3), 76 (26.3), 65 (22.7), 53 (39.4), 50 (44.2)		
3a	3444 (OH), 1735 (C=O _{ester}), 1672 (C=O _{retone}), 1644 (C=O _{quinolone}), 1162 (C-O-C _{ether})	3.48 (s, 3H, NCH ₃), 3.52 (s, 2H, CH ₂), 3.62 (s, 3H, OCH ₃), 7.44 (t, 1H, <i>J</i> = 6.2, 6- H), 7.64 (d, 1H, <i>J</i> = 8, 8- H), 7.76 (t, 1H, <i>J</i> = 6.2, 7- H), 8 (d, 1H, <i>J</i> = 8, 5- H), 13.4 (bs, 1H, OH)	275 (4.8) (M ¹), 276 (1.5), 274(1.9), 261 (9.6), 245 (18.3), 217 (12.4), 203 (13.8), 175 (100), 161 (17.6), 145 (24.4), 117 (16.2), 93 (28.1), 77 (23.2), 64 (16.0), 51 (45.0)		
4	3446- 2500 (OH, NH), 1739 (C=O _{carboxylic}), 1671 (C=O _{ketone} + C=O _{quinolone})	3.50 (s, 3H, NCH ₃), 7.52 (t, 1H, J = 6.4, C7-H), 7.79 (d, 1H, J = 8, C8-H), 7.90 (t, 1H, J = 6.4, C6-H), 8 (d, 1H, J = 8, C5-H), 12.8 (bs, 1H, OH _{oxime}), 13.4 (bs, 1H, OH), 17.6 (bs, 1H, OH _{carboxylic})	290 (M ⁺) (4.9), 291 (1.3), 285 (15.4), 229 (5.4), 228 (13.6), 216 (23.0), 215 (40.3), 202 (18.1), 134 (18.5), 106 (15.7), 77 (75.9), 51 (100)		
5	3432 (OH), 1737 (C=0 _{pyrone}), 1649 (C=O _{quinolone}), 1618 (C=N)	3.50 (s, 3H, NCH ₃), 7.25-7.32 (t, <i>J</i> = 6.9 Hz, 1H, 7-H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H, 8-H), 7.76 (t, <i>J</i> = 6.9 Hz, 1H, 6-H), 7.98 (d, <i>J</i> = 8.0 Hz, 1H, 5-H), 12.8 (s, 1H, OH _{oxime})			
6	3206-2434 (OH _{carboxylic}), 1737 (C=O _{carboxlic}), 1640 (C=O _{quinolone}), 1503, 1481 (NO ₂)	3.73 (s, 3H, NCH ₃), 7.30-8.05 (m, 8H, H _{arom}), 9.17 (bs, 1H, NH), 12.37 (bs, 1H, OH), 15.23 (bs, 1H, OH _{carboxylic})	410 (M+) (5.1), 411(2.3), 394 (20.4), 365 (10.7), 349 (17.9), 321 (32.6), 230 (100), 217 (34.7), 203 (31.8), 175 (56.9)		
7	3404(NH), 1725 -1673 (C=O _{pyrone}), 1631 (C=O _{quinolone}), 1571, 1495 (NO ₂)	3.73 (s, 3H, NCH ₃), 7.33-8.02 (m, 8H, H _{arom}), 9.40 (bs, 1H, NH)	392 (M+) (3.6), 393 (1.8), 347 (8.7), 256 (18.0), 243 (100), 230 (10.4), 217 (40.1), 203 (30.2), 189 (63.3), 175 (34.2), 161 (32.0)		
8	3227 (OH, NH), 1742 (C=O _{carboxylic}), 1674 (C=O _{quinolone})	3.28 (s, 3H, NCH ₃), 3.63 (s, 3H, OCH ₃), 6.89 (d, 1H, <i>J</i> = 8.2, 2-H _{pyrrole}), 7.09 (d, 1H, <i>J</i> = 8.2, 3-H _{Pyrrole}), 7.51 (t, 1H, <i>J</i> = 7.9, 6-H), 7.82 (m, 2H, 7-H + 8-H), 8.10 (d, 1H, <i>J</i> = 7.8, 5-H), 9.64 (bs, 1H, NH), 13.8 (bs, 1H, OH _{carboxylic})	298 (M [.]) (15.9), 299 (5.0), 297 (8.4), 283 (2.9), 269 (8.5), 267 (15.2), 266 (12.0), 254 (21.2), 215 (20.3), 199 (12.2), 159 (14.5), 131 (11.0), 77 (21.1), 76 (18.6), 75 (100)		
10	3429, 3243 (OH, NH), 1740 (C=O _{carboxylic}), 1730 (C=O _{indolone}), 1650 (C=O _{quinolone})	3.71 (s, 3H, NCH ₃), 6.92-8.34 (m, 8H, H _{arom}), 10.42 (bs, 1H, NH), 12.40 (bs, 1H, OH), 14.2 (bs, 1H, OH _{carboxylic})	390 (M [.]) (8.6), 391 (2.6), 346 (34.0), 330 (22.1), 316 (20.2), 173 (34.6), 159 (43.8), 145 (32.7)		
11	3157 (NH), 1752 (C=O _{pyrone}), 1652 (C=O _{indolone} , C=O _{quinolone})	3.52 (s, 3H, NCH ₃), 7.04-8.70 (m, 8H, H _{arom}), 12.01 (bs, 1H, NH)	372 (M [.]) (4.6), 373 (1.7), 331 (23.3), 317(12.5), 255 (100), 241 (10.7), 229 (21.9), 201 (13.3), 200 (15.2), 173 (18.6), 145 (20.2), 78 (21.3)		
12	3435 (OH), 1730 (C=O _{pyrone}), 1636 (C=O _{quinolone})	3.49 (s, 3H, NCH3), 7.37-7.84 (s, 8H, H _{arom}), 8.16 (s, 1H, 4-H _{coumarin}), 14.80 (bs,1H, OH)	347 (M+) (100), 348 (36.0), 349 (6.7), 319 (39.6), 275 (61.9), 202 (38.4), 173 (57.6), 134 (46.5), 90 (23.6), 77 (71.4), 63 (46.8)		
13	3423,(OH), 1670, 1651 (C=O _{pyrone}), 1644 (C=O _{quinolone})	3.52 (s, 3H, NCH ₃), 7.15-7.97 (m, 8H, H _{arom}), 5.68 (s, 1H, H _{methine}), 12.00 (bs, 1H, OH)			
17a	3415 (OH), 1717 (C=O _{pyrone}), 1670 (C=O _{quinolone})	3.70 (s, 3H, NCH ₃), 3.77 (s, 3H, NCH ₃), 5.82 (s, 1H, H _{methine}), 7.30-8.33 (m, 8H, H _{arom}), 13.4 (bs, 1H, OH)	428 (M ⁺) (38.3), 429 (9.4), 400 (31.2), 399(10.9), 385(6.8), 268(16.4), 254 (29.6), 226 (8.3), 214 (11.3), 202 (20.4), 199 (60.6), 172 (14.3), 117 (14.2), 115 (24.0), 104 (38.5), 77 (100), 76 (29.7), 64 (23.3)		
17b	3438, 3158 (OH), 1752 (C=O _{pyrone}), 1657 (C=O _{quinolone})	2.43 (s, 3H, 6CH ₃), 3.49 (s, 3H, NCH ₃), 5.44 (s, 1H, H _{methine}), 7.31-8.05 (m, 7H, H _{arom}), 12.11 (bs, 1H, NH), 13.8 (bs, 1H, OH)	428 (M ⁺) (100), 429 (25.3), 430 (10.6), 427 (11.3), 400 (74.2), 399 (18.2), 372 (27.3), 226 (21.4), 200 (25.4), 199 (97.6), 186 (22.6), 39 (12.8), 104 (55.6), 77 (99.9)		
20	3051 (C-H _{arom}), 1748 (C=O _{pyrone}), 1644 (C=O _{pyrone}), 1622 (C=O _{quinolone})	(CDCl ₃) 3.84 (s, 3H, NCH ₃), 6.94 (s, 1H, H _{methine}), 7.12 (d, 1H, <i>J</i> = 7.9, 6-H _{quinolinone}), 7.44 -7.53 (m, 4H, H _{aron}), 7.74 (d, 1H, <i>J</i> = 8.2, 8-H _{chromone}), 8.17 (d, 1H, <i>J</i> = 8.0, 5-H _{quinolone}), 8.37 (d, 1H, <i>J</i> = 8.2, 5-H _{chromone}), 8.70 (s, 1H, 2-H _{chromone})	399 (M [.]) (5.4), 400 (2.2), 398 (25.4), 397 (100), 396 (35.8), 368 (30.4), 277 (81.6), 276 (18.3), 104 (11.4), 93 (28.2), 77 (36.2), 65 (67.2)		

[†]All ¹H NMR experiments were carried out in DMSO-*d*₆ unless cited.





2.14. 3-(2-Hydroxybenzylidene)-6-methylpyrano[3,2-c] quinoline-2,4,5(3H,6H)-trione (13)

A mixture of the compound **1** (2.43 g, 10 mmol), salicylaldehyde (1 mL, 10 mmol), and fused sodium acetate (2.05 g, 25 mmol), in acetic acid (20 mL), was heated under reflux for 4 hr. The pale-yellow precipitate so formed was filtered, washed twice with water and ethanol, and crystallized to give the compound **13** (Scheme 4) (Table 1 and 2).

2.15. 3-((4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3yl)methylene)-6-methyl-2H-pyrano[3,2-c]quinoline-2,4,5 (3H,6H)-trione (17a) and 3-((4-Hydroxy-6-methyl-2-oxo-1,2dihydroquinolin-3-yl)methylene)-6-methyl-2H-pyrano[3,2c]quinoline-2,4,5(3H,6H)-trione (17b)

A mixture of the compound **2** (0.52 g, 2 mmol), the proper aldehyde derivative **14a** [22], **14b** [23], (0.41 g, 2 mmol), and freshly fused sodium acetate (0.82 g, 10 mmol), in glacial acetic

acid (20 mL) was heated under reflux for 4 hr. The crystalline precipitate that formed was collected by filtration, washed with cold ethanol (10 mL) and diethyl ether (10 mL), and recrystallized to give the corresponding pyranoquinoline **17a** and **17b** (Scheme 5) (Table 1 and 2).

2.16. 6-Methyl-3-((4-oxo-4H-chromen-3-yl)methylene)-2Hpyrano[3,2-c]quinoline-2,4,5(3H,6H)-trione (20) and (E)-4-Hydroxy-1-methyl-3-(3-(4-oxo-4H-chromen-3-yl) acryloyl) quinolin-2(1H)-one (21)

A mixture of the compound **2** (0.52 g, 2 mmol), 4-oxo-4*H*chromene-3-carbaldehyde (**18**) [24] (0.35 g, 2 mmol), and freshly fused sodium acetate (0.82 g, 10 mmol), glacial acetic acid (20 mL), was refluxed for 5 hr. The brown precipitate so separated was filtered, washed with cold water, dried and crystallized from hot DMF (20 mL) to give reddish-brown prisms (0.52 g) of the chromenylpyranoquinline **20** (Scheme 5) (Table 1 and 2). The DMF-mother liquor filtrate of crystallization was evaporated to about one-third of its initial volume to give yellowish brown needles (0.10 g) of the chromenylacryloylquinoline **21** [25] (Scheme 5) (Table 1 and 2).

3. Results and discussion

It was reported that boiling of pyranoquinolinone 1 in aqueous sodium hydroxide results in 3-acetyl-4hydroxyquinolin-2(1H)-one in which ring-opening is followed by decarboxylation [14,26]. Our attempts to obtain a quinolinone bearing β-keto carboxylic acid group at position-3 met success, starting from pyranoquinolinone 1. A convenient facile basic hydrolysis of pyranoquinolinone 1 was carried out via warming its aqueous sodium hydroxide solution at about 50 °C, to give 3-(4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-3-oxopropanoic acid (2) in 94 % yield (Scheme 1). The structure of the product was established on basis of the following analytical and spectral results; satisfactory elemental microanalysis for C, H, and N elements is within ±0.2 % (Table 1), IR spectrum revealed the presence of absorption bands at v 3447 and 1734 cm⁻¹ due to CO₂H group, ¹H NMR spectrum, in dimethylsulfoxide (DMSO-d₆), showed that it exists as 4hydroxyquinolin-2-one form, while in chloroform (CDCl3) it exists as 2,4-quinolinedione form. In CDCl3 the proton at position-3 was observed at δ 5.66 (Table 2), and mass spectrum presented molecular ion peak M⁺ at m/z 261 and a peak at m/z 243 due to (M-H₂O)+ ion of a recyclized pyranoquinoline fragment (Table 2).

Alkyl 3-(quinolinyl)-3-oxopropanoates 3a,b were obtained via esterification of the β -keto acid 2 with alcohols viz; methanol and ethanol, in presence of concentrated sulfuric acid, in 84 ± 1 % yields (Scheme 1). ¹H NMR spectrum of compound **3a** (R = Et) showed signals at δ 3.48 due to (NCH₃), 3.52 due to (α -CH₂CO₂Me), and 3.62 due to (CO₂CH₃). An alternative route to obtain the ester 3b (R = Et) was described via Claisen condensation reaction between diethyl carbonate and 3-acetyl-4-hydroxy-1-methylquinolin-2(1*H*)-one [21]. However, the present preparation from compound $\mathbf{2}$ is convenient and advantageous because Claisen condensation, in which many by-products are formed and purification of the product is inconvenient, with overall yield \sim 44 %, starting from pyranoquinoline 1, a nearly half of the present preparation vield [17].

Nitrosation of the β -keto acid 2, using sodium nitrite and dilute hydrochloric acid at 0-5 °C, furnished 3-(quinolin-3-yl)-2-oximo-3-oxopropannoic acid 4. As depicted in Scheme 2, the oxime 4 may exist in two forms; Z-form 4 and/or E-form 4'. 1H NMR spectrum of compound **4** showed three signals at δ 12.8, 13.4, and 17.6 (Table 2). Since the three chemical shifts disappear on deutration, they attributed to three OH groups of oxime, quinolinol, and carboxylic acid, respectively. The dehydration reaction of the oxime 4, in concentrated sulfuric acid, is expected to give one or more than one product. The structures which are suggested as possible products for such reaction include; 3-oximopyrano[3,2-c]quinolinetrione 5 and 1,2-oxazino[5,6-c]quinoline-3-carboxylic acid, (Scheme 2). In addition to chemical tests, IR and ¹H NMR spectral data of the product showed no evidences for presence of CO₂H. So it is concluded that the product of this reaction is the compound 5. Moreover, these results were clearly supported by obtaining of the pyranoquinoline 5 directly from nitrosation of pyranoquinoline 1 (Scheme 2).

The coupling reaction of β -keto acid **2** with *p*nitrobenzenediazonium chloride afforded an orange colored product. IR spectrum of the product showed a medium absorption band broaden between 3206-2434 cm⁻¹ due to Hbonded N-H and O-H, in addition to two strong stretching bands at 1737 and 1640 cm⁻¹ due to C=O of carboxylic acid and quinolinone. ¹H NMR spectrum revealed the presence of three D-exchangeable protons at δ 9.17, 12.37, and 15.23 refer to N-H of hydrazone and O-H of quinolinol and carboxylic acid. Building on above the structure of the product was determined as 3-quinolinyl-2-(4-nitrophenylhydrazono)-3-oxopropionic acid **6**. Herein again the *Z*-form **6** and *E*-form **6'** are possible as depicted in Scheme 2. The structures of compounds **4** and **6** as seen need further study using X-ray single crystal analysis but unfortunately we did not succeed in getting suitable crystals for such analysis.

When the compound **6** was subjected to dehydration using concentrated sulfuric acid only 3-hydrazonopyrano[3,2c]quinolinetrione **7** was obtained. For such reaction one can also expect to get pyridazino[4,3-c]quinoline-3-carboxylic acid by the possible intramolecular heterocyclization between hydrazone nitrogen and quinolinol hydroxyl group. All analytical and spectral data showed that carboxylic group was involved in cyclization and structure of the product contains an N-H appeared at δ 9.64 (exchangeable on deutration). Moreover, these results were definitely confirmed when the same hydrazone derivative **7** was obtained *via* coupling of the pyranoquinolinedione **1** with *p*-nitrobenzenediazonium chloride (Scheme 2).

The reaction of the β -keto acid **2** with 2,2dimethoxyethanamine (2-aminoacetaldehyde dimethyl acetal), in boiling DMF, was carried out to obtain a 2-(quinolin-3yl)pyrrole-3-carboxylic acid derivative. Unexpectedly, characterization of structure of the product using elemental and spectral analyses indicated the existence of a methoxy and a carboxylic acid functions. Mass fragmentation pattern revealed peaks at m/z 267 due to (M - OCH₃)+ ion and m/z 254 due to (M - CO₂)⁺ ion (Table 2). ¹H NMR spectrum showed a singlet signal at δ 3.63 due chemical shift of OCH3 in addition to two deuterium replaceable protons appeared at δ 9.64 and 13.8 due to pyrrole N-H and carboxylic O-H (Table 2). As depicted in scheme 3. Friedländer cvclo-condensation reaction took place. giving the corresponding azomethine intermediate, which underwent an intramolecular S_N2 O-methylation of 4hydroxyquinolin-2-one, accompanied by loss of methanol. The presumed aldehyde intermediate underwent smooth cyclization, leading to 2-(4-methoxy-1-methyl-2-oxo-1,2dihydroquinolin-3-yl)-1*H*-pyrrole-3-carboxylic acid (8) (Scheme 3).

As illustrated in scheme 3, when the β -keto acid 2 was subjected to react with hydrazine hydrate, in boiling DMF, the pyrazolinylquinoline 9 was obtained, in moderate yield (56 %). The same compound was also obtained starting from the pyranoquinolinedione 1 as previously described by us [16]. Even, the reported preparation yield (92%) is higher than the present but usage of β -keto acid **2** in preparation is mandatory for estimation of orientation of cyclization. In case of γ hydroxy- α -pyrone, the nucleophilic attack starts at lactone C=O followed by cyclization with nucleophilic replacement of the γ enol OH, while in case of β-keto acid this attack should start at the β -C=O followed by cyclization with cyclo-condensation with the carboxylic group. Anyhow in case of treatment with hydrazine no difference is noticed but we expect that both compounds 1 and 2 may give different products on use of unsymmetrical 1,2-binucleophiles like mono-substituted hydrazine and hydroxylamine.

Treatment of the β -keto acid **2** with isatine was carried out under Knoevenagel reaction conditions using fused sodium acetate and glacial acetic acid. The product of this reaction was characterized as 3-quinolinyl-3-oxo-2-(indol-3-ylidene) propanoic acid **10** (Scheme 4). Under this acidic conditions, it was expected to obtain the cyclization product; indolylidene pyranoquinoline **11**.



Scheme 5

However, when the product **10** was consequently treated with concentrated sulfuric acid, this cyclization took place and the compound **11** was formed. Interestingly, when the pyranoquinoline **1** was subjected to react with isatine, in presence of fused sodium acetate and glacial acetic acid, the same compound **11** was afforded, in 88 % yield (Scheme 4).

Since benzopyrones are well thought-out as useful synthons to get diverse heterocyclic derivatives through ringopening ring closure (RORC) reactions [27-30], it was planned to obtain a new quinolinone derivatives in which benzopyrone nucleus was constructed as substituent at position-3. Thus, β -keto acid 2 was subjected to react with salicylaldehyde, in presence of piperidine in boiling ethanol. Both coumarin derivative 12 and pyranoquinoline derivative 13 were expected as products of this reaction (Scheme 4). For such reaction the plausible Knoevenagel condensation intermediate was suggested due to the reactivity of methylene of the β -keto acid 2. This intermediate can undergo intramolecular nucleophilic lactonization, forming either coumarin derivative 12 or pyranoquinoline derivative 13.

The elemental and mass analyses of the product are not differential because both expected structures are isomers. ¹H NMR spectrum of the product gave important information about characterization of its structure. Thus, it exhibited a singlet signal at δ 8.16, which is characteristic for chemical shift of C-H at position 4 of α -pyrone. This indicates that the structure of the product is the coumarin **12** (Scheme 4). Interestingly, we checked this result by an alternate route when we carried out the reaction of salicylaldehyde with pyranoquinoline **1**, in acidic medium to retain the pyrone nucleus during the reaction. This reaction was constructed

building on the presence of 4-hydroxy-2-pyrone as malonyl heterocycles, a tautomeric 1,3-dione form, which possesses an active methylene site. Thus, this condensation was carried out, in presence of fused sodium acetate and glacial acetic acid, to give a single product which was found to be different from the coumarin derivative **12**. Again ¹H NMR was used to distinguish the structure of the product in which a methine proton was observed in the normal olefinic region as singlet at δ 5.68. These results confirmed that the latter product is the expected structure of 3-benzylidenepyrano[3,2-*c*]quinolinetrione **13** (Scheme 4).

Knoevenagel condensation of the β -keto acid 2 with quinoline-3-carbaldehydes 14a,b was carried out, in the presence of freshly fused sodium acetate in glacial acetic acid aiming to get the acrylic acid derivative 15. Albeit, the expected acrylic acid derivative 15 was not isolated, its cyclized products 3-(quinolinylmethylene)pyrano[3,2-c]quinolinetriones 17a,b were obtained (Scheme 5). The structure of the products was established on basis of their spectral and analytical data, which showed the disappearance of the carboxylic group and the presence of only one hydroxyl group. It is worthwhile to take into account the other reasonable isomeric structure 16. Elemental microanalyses and IR spectra did not give significant information to deduce which structure 16 or 17 is the product. ¹H NMR spectrum showed singlet peak due to chemical shift of olefinic C-H proton appeared at δ 5.82 corresponding to compound **17a**, and at δ 5.44 corresponding to compound **17b**. These results confirmed the proposed lactonization, excluding formation of structure 16. There is no explanation for these results other than the formation of Z-intermediate 15 which is stabilized through the extended conjugation of the chain HO-

C=C-CH=C-C=OOH, in addition to additional stabilization comes from intramolecular H-bonding between carboxylic function and its neighbouring hydroxy and oxo functions (Scheme 5)

The β -keto acid **2** was subjected to react with 4-oxo-4*H*chromene-3-carbaldehyde (18), in presence of fused sodium acetate. This reaction led to the formation of two isolable products. Characterization of the two products proved that the major product is 3-(chromenylmethylene)pyrano[3,2clquinolinetrione 20. The minor product, which was separated from the DMF filtrate of crystallization of reaction product, was characterized as 3-(3-chromenyl)acryloylquinolinone 21 (Scheme 5). The structure of the major product pyranoquinoline 20 was inferred from its elemental and spectral analytical data. Microanalysis for C, H, and N elements showed satisfactory results (within ± 0.4 %) of the calculated values (Table 1). IR spectrum represented strong stretching band at v 1748 correlated to C=O groups of α -pyrone, and 1644-1622 cm⁻¹ due to C=O groups of γ -pyrone and quinolone. ¹H NMR spectrum showed singlet signal at δ 6.94 due to chemical shift of a methine proton. Moreover, three signals were also observed at more down field shifts at δ 8.17 as doublet due to C5-H of quinoline, 8.37 as doublet due to C5-H of γ -chromone, and δ 8.70 as singlet characteristic for C2-H of chromone (Table 2). Mass spectrum revealed molecular ion peak at m/z 399, which is in agreement with the calculated molecular weight for the formula (Table 2). The minor product acryloylquinoline **21** is a known compound previously prepared by condensation of 3-acetyl-4-hydroxy-1methylquinolin-2(1*H*)-one and 4-oxo-4H-chromene-3carbaldehyde (18) [25]. An authentic sample of the compound 21 was compared with this product and found completely identical. This showed that subsequent to condensation to form the intermediate 19, partial decarboxylation took place to some extent affording the acryloylquinoline 21, while the majority cyclized to give the major product pyranoquinoline 20 (Scheme 5).

4. Conclusion

4-Hydroxypyranoquinolinedione **1** and its alkaline hydrolysis product β -keto acid derivative **2** are useful synthons to obtain some new 3-heterocyclic substituted quinoline-2(1*H*)-one derivatives in good yields. Usage of either compound **1** or **2** in condensation reaction with aldehydes can lead to the same products since a facile lactonization of the β -keto acid products takes place in acid media.

References

- [1]. Abass, M.; Mostafa, B. B. Bioorg. Med. Chem. 2005, 13, 6133-6144.
- [2]. El-Shennawy, A. M.; Mohamed, A. H.; Abass M. Gen. Med. J. 2007, 9, 15-33.
- [3]. Detsi, A.; Bouloumbasi, D.; Prousis, K. C.; Koufaki, M.; Athanasellis, G.; Melagraki, G.; Afantitis, A.; Igglessi-Markopoulou, O.; Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Med. Chem. 2007, 50, 2450-2458.
- [4]. Rivkin, A.; Kim, Y. R.; Goulet, M. T.; Bays, N.; Hill, A. D.; Kariv, I.; Krauss, S.; Ginanni, N.; Strack, P. R.; Kohl, N. E.; Chung, C. C.; Varnerin, J. P.; Goudreau, P. N.; Chang, A.; Tota, M. R.; Munoz, B. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4620-4623.
- [5]. Tani, M.; Harimaya, K.; Gyobu, Y.; Sasaki, T.; Takennouchi, O.; Kawamura, T.; Kamimura, T.; Harada, T. J. Antibiot. 2004, 57, 89-96.
- [6]. Snider, B. B.; Wu X. Heterocycles 2006, 70, 279-294.
- [7]. Ahvale, A. B.; Prokopcová, H.; Šefčovičová, J.; Steinschifter, W.; Täubl, A. E.; Uray, G.; Stadlbauer, W. Eur. J. Org. Chem. 2008, 563-571.
- [8]. Ukrainets, I. V.; Tkach, A. A.; Yang, L. Y. Khim. Geterotsikl. Soedin. 2008, 1655-1663; Chem. Heterocycl. Compds. (Engl. Transl.) 2008, 44, 1347-1354.
- [9]. Mohamed, E. A.; Ismail, M. M.; Gabr, Y.; Abass, M.; Farrag, H. A. Indian J. Chem. 1995, 34B, 21-26.
- [10]. Mohamed, E. A.; Ismail, M. M.; Gabr, Y.; Abass, M. J. Serb. Chem. Soc. 1993, 58, 737-743.

- [11]. Stadlbauer, W.; Badawey, E.; Hojas, G.; Roschger, P.; Kappe T. Molecules 2001, 6, 338-352.
- [12]. Watters, W. H.; Ramachandran, V. N. J. Chem. Research (s) 1997, 184-185, 1201-1215.
- [13]. O'Donnell, F.; Smyth, T. J. P.; Ramachandran, V. N.; Smyth, W.F. Inter. J. Antimicrob. Agents 2010, 35, 30-38.
- [14]. Kammerer, F. J.; Gebert, U.; Alpermann, H. G., U. S. Pat. 1981, US 04 258,046; Chem. Abstr. 1982, 95, 22612s.
- [15]. Kappe, T.; Aigner, R.; Hohengassner, P.; Stadlbauer W. J. Prakt Chem. Chem.-Ztg. 1994, 336, 596-601.
- [16]. Abass, M.; Othman, E. S. Synth. Commun. 2001, 31, 3361-3376.
- [17]. Mohamed, E. A.; Gabr, Y.; Ismail, M. M.; Abass, M. An. Quim. 1995, 91, 579-584.
- [18]. Razzag, T.; Kappe, C. O. Tetrahedron Lett. 2007, 48, 2513-2517.
- [19]. Bowman, R. E.; Campbell, A.; Tanner, E. M. J. Org. Chem. 1959, 444-447.
- [20]. Bosson, J. A.; Rasmussen, M.; Ritchie, E.; Robertson, A. V.; Taylor, W. C. Australian J. Chem. 1963, 16, 480-490.
- [21] Ibrahim, S. S.; Allimony, H. A.; Othman, E. S. Chem. Papers 1997, 51, 33-42.
- [22]. Abass, M.; Ismail, M. M. Chem. Papers 2000, 54, 187-195.
- [23]. Mohamed, E. A., Ismail, M. M.; Gabr, Y.; Abass M. Chem. Papers 1994, 48, 285-292.
- [24]. Nohara, A.; Umetani, T.; Sanno, Y. Tetrahedron **1974**, *30*, 3553-3561.
- [25]. Abass, M.; Abdel-Megid, M.; Hassan, M. M. Synth. Commun. 2007, 37, 329-352.
 [26]. Kappe, T.; Ajili S.; Stadlbauer, W. J. Heterocycl. Chem. 1988, 25, 463-
- 468. [27]. Froggett, J. A.; Hockly, M. H.; Titman, R. B. J. Chem. Research (s) **1997**,
- 30-31. [28]. Jacquot, Y.; Refouvelet, B.; Bermont, L.; Adessi, G. L.; Leclercq, G.;
- Jacquot, F., Facherete, B., Jachinson, J., Jacob, A. & Jackeret, G., Xicluna, A. Pharmazie 2002, 57, 233-237.
 [29]. Refouvelet, B.; Guyon, C.; Jacquot, Y.; Girard, C.; Fein, H.; Bévalot, F.;
- [15] Robert, J. F.; Heyd, B.; Mantion, G.; Richert, L.; Xicluna, A. J. Chem. Soc. 2004, 39, 931-937.
- [30]. Alvim, J.; Dias, R. L. A.; Castilho, M. S.; Oliva, G.; Correa, A. G. J. Braz. Chem. Soc. 2005, 16, 763-773.